Argenica Therapeutics Ltd (AGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Argenica Therapeutics Ltd (AGN) has a cash flow conversion efficiency ratio of -1.602x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-5.51 Million ≈ $-3.90 Million USD) by net assets (AU$3.44 Million ≈ $2.44 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Argenica Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Argenica Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Argenica Therapeutics Ltd total liabilities for a breakdown of total debt and financial obligations.
Argenica Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Argenica Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RPCG Public Company Limited
BK:RPC
|
-0.007x |
|
Janfusun Fancyworld
TWO:5701
|
0.066x |
|
Mega Polietilen Kopuk Sanayi ve Ticaret AS
IS:MEGAP
|
-0.371x |
|
Middle Island Resources Ltd
AU:MDI
|
-0.200x |
|
MyTech Group Bhd
KLSE:7692
|
0.081x |
|
Cubex Tubings Limited
NSE:CUBEXTUB
|
0.005x |
|
Immo Moury SICAF Immobiliere Publique de Droit Belge
BR:IMMOU
|
0.026x |
|
Torrent Capital Ltd
V:TORR
|
0.075x |
Annual Cash Flow Conversion Efficiency for Argenica Therapeutics Ltd (2019–2024)
The table below shows the annual cash flow conversion efficiency of Argenica Therapeutics Ltd from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Argenica Therapeutics Ltd (AGN) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | AU$7.24 Million ≈ $5.12 Million |
AU$-5.70 Million ≈ $-4.04 Million |
-0.788x | -117.29% |
| 2023-12-31 | AU$13.95 Million ≈ $9.87 Million |
AU$-5.06 Million ≈ $-3.58 Million |
-0.363x | +15.74% |
| 2022-12-31 | AU$7.67 Million ≈ $5.42 Million |
AU$-3.30 Million ≈ $-2.34 Million |
-0.430x | -6.38% |
| 2021-12-31 | AU$8.31 Million ≈ $5.88 Million |
AU$-3.36 Million ≈ $-2.38 Million |
-0.405x | -164.77% |
| 2020-12-31 | AU$6.85 Million ≈ $4.84 Million |
AU$-1.05 Million ≈ $-740.40K |
-0.153x | +95.22% |
| 2019-12-31 | AU$18.40K ≈ $13.02K |
AU$-58.82K ≈ $-41.62K |
-3.197x | -- |
About Argenica Therapeutics Ltd
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Aus… Read more